December 07, 2020 16:00 ET | Source: INVENTIVA multilang-release Daix (France), December 7, 2020 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the publication of a scientific paper on the beneficial effects of lanifibranor on experimental advanced chronic liver disease (ACLD) by the peer-reviewed scientific journal Journal of Hepatology. The article, entitled The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease, discusses the effects of Inventivas lead drug candidate lanifibranor, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist, in two distinct pre-clinical models of cirrhosis and in human liver cells from cirrhotic patients Continue reading →

By Hub staff report Five Johns Hopkins faculty members have been elected as fellows of the National Academy of Inventors, a prestigious distinction that recognizes and honors the creators or co-developers of outstanding inventions that have made a difference in society. These professors join the more than 4,000 current fellows of the academy, which features members of more than 250 institutions worldwide. The honorees from Johns Hopkins are: Ramalingam Chellappa, who joined the Hopkins Department of Biomedical Engineering and the Department of Electrical and Computer Engineering as a Bloomberg Distinguished Professor earlier this year Continue reading →

December 07, 2020 07:00 ET | Source: Imara, Inc. Preliminary data as of August 2020 from ongoing Phase 2a open label extension trial showed increases in HbF percentage and F-cells after approximately six months of treatment Case reports showed additional improvements in clinical outcomes, hemoglobin and related biomarkers of hemolysis IMR-687 continued to be well tolerated as a monotherapy and in combination with hydroxyurea BOSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. Continue reading →

BOSTON, Dec. 8, 2020 /PRNewswire/ --Emulate, Inc., a leading provider of advanced in vitro models, today announced that its Alveolus Lung-Chip is being used by the U.S Continue reading →

Dementia: Expert discusses the signs and symptoms There are over 200 subtypes of dementia but the third most common (behind Alzheimer's disease and vascular dementia) is thought to be Lewy body dementia (LBD). It is associated with abnormal deposits in the brain. These deposits, called Lewy bodies, affect chemicals in the brain, which in turn can lead to problems with thinking, movement, behaviour, and mood. Continue reading →